Complex Trial Models Increase the Need for Risk-Advisory Brokerage

Clinical research insurance brokerage services in Latin America are moving beyond policy placement as trial designs become more complex. Sponsors are running oncology, rare disease, device, decentralized and first-in-human studies across regional markets, which changes the risk profile and insurance needs before enrollment begins.

The region is attracting more research activity because sponsors want recruitment access and diversified trial footprints. Towards Healthcare estimates that the Latin America clinical trials market will grow from USD 5.0 billion in 2026 to USD 9.17 billion by 2035, while the region’s pharmaceutical contract manufacturing and research services market is forecast to grow from USD 24.09 billion in 2026 to USD 43.99 billion by 2035.

This expansion increases demand for brokers that can advise on trial risk rather than merely obtain a certificate. A low-risk observational study, a device implantation trial and an early-stage oncology study do not create the same insurance exposure. Coverage limits, exclusions and policy wording should reflect participant risk and sponsor obligations.

Operational complexity also matters. A trial may involve several countries, multiple CRO partners, public hospitals, private sites and different investigator contracts. The insurance program must align with indemnity clauses and local legal expectations. When those documents conflict, startup teams can face delays or coverage uncertainty.

Clinical trials are already exposed to operational risk. A 2026 machine-learning study on trial success notes that clinical trials involve high costs, long timelines and substantial operational risk, with success depending on initiation, conduct, recruitment targets and protocol completion. Insurance brokerage cannot solve all these risks, but it can reduce uncertainty around participant injury liability and sponsor financial exposure.

Protection of participants is crucial. The insurance should allow for procedures for providing compensation in case of injury caused by participation in the study. In jurisdictions where the knowledge about clinical trials might not be as widespread as elsewhere, proper insurance documentation will increase the confidence of ethics boards, researchers and patients.

The broker should also ensure that sponsors do not have any discrepancies between the global risk management and the local one. The master policy might provide comprehensive cover, but it does not mean that local laws, ethics reviews or site agreements require certain documentation. Proper brokerage will synchronize these three before it becomes an issue.

Decentralized elements may add new questions. Remote visits, home nursing, device shipment and digital monitoring can create exposures outside the traditional research site. Brokers may need to review whether coverage extends to these activities and whether vendors should be added or separately insured.

The next phase of clinical research insurance in Latin America will likely favor brokers that operate as risk advisors inside the trial-startup process. Sponsors need support that connects insurance, contracts and regulatory submissions.

Clinical research insurance brokerage services in Latin America are becoming part of trial-risk management. Their strongest value will come from helping sponsors protect participants, satisfy local requirements and keep complex studies moving toward activation.